- cafead   Sep 27, 2023 at 11:12: PM
via Gilead Sciences’ anti-CD47 antibody has again disappointed in a Phase III blood cancer trial. The biopharma announced the decision to discontinue another late-stage study of magrolimab Tuesday.
article source
article source